Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations.
EXPeRT
PARTNER
adolescents
adrenocortical tumours
children
diagnosis
guidelines
recommendations
therapy
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
02
03
2021
received:
09
02
2021
accepted:
07
03
2021
entrez:
26
6
2021
pubmed:
27
6
2021
medline:
6
5
2022
Statut:
ppublish
Résumé
Adrenocortical tumours (ACTs) are rare during childhood. A complete surgical resection provides the best chance of cure, but the role and efficacy of the adjuvant therapy are still controversial. Various histologic criteria of malignancy for ACTs adopted in children do not facilitate comparative studies and are not completely shared. Therefore, a sharp demarcation between benign and malignant lesions has not been recognised, making it difficult to identify who potentially needs perioperative therapy. This manuscript presents the internationally harmonised recommendations for the diagnosis and treatment of ACTs in children and adolescents, established by the European Cooperative Study Group for Paediatric Rare Tumours (EXPeRT) group within the EU-funded project PARTNER (Paediatric Rare Tumours Network - European Registry).
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29025Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Dall'Igna P, Virgone C, De Salvo GL, et al. Adrenocortical tumours in Italian children: analysis of clinical characteristics and P53 status. Data from the national registries. J Pediatr Surg. 2014;49(9):1367-1371.
Wasserman JD, Novokmet A, Eichler-Jonsson C, et al. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study. J Clin Oncol. 2015;33(6):602-609.
Ribeiro RC, Sandrini Neto RS, Schell MJ, Lacerda L, Sambaio GA, Cat I. Adrenocortical carcinoma in children: a study of 40 cases. J Clin Oncol. 1990;8(1):67-74.
Rodriguez-Galindo C, Figueiredo BC, Zambetti GP, Ribeiro RC. Biology, clinical characteristics, and management of adrenocortical tumours in children. Pediatr Blood Cancer. 2005;45(3):265-273.
Custódio G, Komechen H, Figueiredo FRO, Fachin ND, Pianovski MAD, Figueiredo BC. Molecular epidemiology of adrenocortical tumours in southern Brazil. Mol Cell Endocrinol. 2012;351(1):44-51.
Wieneke JA, Thompson LDR, Heffess CS. Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. Am J Surg Pathol. 2003;27(7):867-881.
Jehangir S, Nanjundaiah P, Sigamani E, et al. Pathological prognostication of pediatric adrenocortical tumours: is a gold standard emerging? Pediatr Blood Cancer. 2019;66(4):e27567.
Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A. 2001;98(16):9330-9335.
Latronico AC, Pinto EM, Domenice S, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab. 2001;86(10):4970-4973.
Das S, Sengupta M, Islam N, et al. Weineke criteria, Ki-67 index and p53 status to study pediatric adrenocortical tumours: is there a correlation? J Pediatr Surg. 2016;51(11):1795-1800.
Chatterjee G, DasGupta S, Mukherjee G, et al. Usefulness of Wieneke criteria in assessing morphologic characteristics of adrenocortical tumours in children. Pediatr Surg Int. 2015;31(6):563-571.
Teinturier C, Pauchard MS, Brugières L, Landais P, Chaussain JL, Bougnères PF. Clinical and prognostic aspects of adrenocortical neoplasms in childhood. Med Pediatr Oncol. 1999;32(2):106-111.
Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumours: a report from the International Pediatric Adrenocortical Tumour Registry. J Clin Oncol. 2004;22(5):838-845.
Zambaiti E, Duci M, De Corti F, et al. Clinical prognostic factors in pediatric adrenocortical tumours: a meta-analysis. Pediatr Blood Cancer. 2021;68(3):e28836.
Picard C, Orbach D, Carton M, et al. Revisiting the role of the pathological grading in pediatric adrenal cortical tumours: results from a national cohort study with pathological review. Mod Pathol. 2019;32(4):546-559.
Picard C, Faure-Conter C, Leblond P, et al. Exploring heterogeneity of adrenal cortical tumours in children: the French pediatric rare tumour group (FRACTURE) experience. Pediatr Blood Cancer. 2020;67(2):e28086.
Cecchetto G, Ganarin A, Bien E, et al. Outcome and prognostic factors in high-risk childhood adrenocortical carcinomas: a report from the European Cooperative Study Group on Pediatric Rare Tumours (EXPeRT). Pediatr Blood Cancer. 2017;64(6):e26368.
Dykewicz CA, Centers for Disease Control and Prevention (U.S.), Infectious Diseases Society of America, American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139-144.
Orbach D, Ferrari A, Schneider D, et al. The European Pediatric Rare Tumors Network - European Registry (PARTNER) Project on very rare tumors in children. Pediatr Blood Cancer. 2021. In press.
Redlich A, Boxberger N, Strugala D, et al. Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial. Klin Padiatr. 2012;224(6):366-371.
McAteer JP, Huaco JA, Gow KW. Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study. J Pediatr Surg. 2013;48(5):1025-1031.
Gulack BC, Rialon KL, Englum BR, et al. Factors associated with survival in pediatric adrenocortical carcinoma: an analysis of the National Cancer Data Base (NCDB). J Pediatr Surg. 2016;51(1):172-177.
Williams AR, Hammer GD, Else T. Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome. Eur J Endocrinol. 2014;170(6):829-835.
Ribeiro RC, Pinto EM, Zambetti GP, Rodriguez-Galindo C. The International Pediatric Adrenocortical Tumour Registry initiative: contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumours. Mol Cell Endocrinol. 2012;351(1):37-43.
Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989;13(3):202-206.
Dehner LP, Hill DA. Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survivors? Pediatr Dev Pathol. 2009;12(4):284-291.
Dehner LP. Pediatric adrenocortical neoplasms: on the road to some clarity. Am J Surg Pathol. 2003;27(7):1005-1007.
Sandrini R, Ribeiro RC, DeLacerda L. Childhood adrenocortical tumours. J Clin Endocrinol Metab. 1997;82(7):2027-2031.
Rodriguez-Galindo C, Pappo AS, Krailo MD, et al. Treatment of childhood adrenocortical carcinoma (ACC) with surgery plus retroperitoneal lymph node dissection (RPLND) and multiagent chemotherapy: results of the Children's Oncology Group ARAR0332 protocol. J Clin Oncol. 2016;34:10515.
Fascetti-Leon F, Scotton G, Pio L, et al. Minimally invasive resection of adrenal masses in infants and children: results of a European multi-center survey. Surg Endosc. 2017;31(11):4505-4512.
Heloury Y, Muthucumaru M, Panabokke G, Cheng W, Kimber C, Leclair MD. Minimally invasive adrenalectomy in children. J Pediatr Surg. 2012;47(2):415-421.
Cundy TP, Marcus HJ, Clark J, et al. Robot-assisted minimally invasive surgery for pediatric solid tumours: a systematic review of feasibility and current status. Eur J Pediatr Surg. 2014;24(2):127-135.
Meignan P, Ballouhey Q, Lejeune J, et al. Robotic-assisted laparoscopic surgery for pediatric tumours: a bicenter experience. J Robot Surg. 2018;12(3):501-508.
St Peter SD, Valusek PA, Hill S, et al. Laparoscopic adrenalectomy in children: a multicenter experience. J Laparoendosc Adv Surg Tech A. 2011;21(7):647-649.
Hedican SP, Marshall FF. Adrenocortical carcinoma with intracaval extension. J Urol. 1997;158(6):2056-2061.
Hubertus J, Boxberger N, Redlich A, von Schweinitz D, Vorwerk P. Surgical aspects in the treatment of adrenocortical carcinomas in children: data of the GPOH-MET 97 trial. Klin Padiatr. 2012;224(3):143-147.
Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-2197.
Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005;12(3):657-666.
Fassnacht M, Dekkers O, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumours. Eur J Endocrinol. 2018;179(4):G1-G46.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
Liang R, Weigand I, Lippert J, et al. Targeted gene expression profile reveals CDK4 as therapeutic target for selected patients with adrenocortical carcinoma. Front Endocrinol (Lausanne). 2020;11:219.
Lotfi Shahreza M, Ghadiri N, Green JR. A computational drug repositioning method applied to rare diseases: adrenocortical carcinoma. Sci Rep. 2020;10(1):8846.
Altieri B, Ronchi CL, Kroiss M, Fassnacht M. Next-generation therapies for adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2020;34(3):101434.
Megerle F, Kroiss M, Hahner S, Fassnacht M. Advanced adrenocortical carcinoma - what to do when first-line therapy fails? Exp Clin Endocrinol Diabetes. 2019;127(2-3):109-116.
Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322(17):1195-1201.
Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994;69(5):947-951.
Dickstein G, Shechner C, Arad E, Best LA, Nativ O. Is there a role for low doses of mitotane (o,p’-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab. 1998;83(9):3100-3103.
Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372-2380.
Zancanella P, Pianovski MAD, Oliveira BH, et al. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumour regression. J Pediatr Hematol Oncol. 2006;28(8):513-524.
Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35(2):282-326.
Sabolch A, Else T, Griffith KA, et al. Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2015;92(2):252-259.
Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-389.
Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG, The European Reference Network GENTURIS. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020;28(10):1379-1386.
Kratz CP, Achatz MI, Brugières L, et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res. 2017;23(11):e38-e45.